Transmission event of SARS-CoV-2 delta variant reveals multiple vaccine breakthrough infections

BMC Med. 2021 Oct 1;19(1):255. doi: 10.1186/s12916-021-02103-4.

Abstract

Background: This study aims to identify the causative strain of SARS-CoV-2 in a cluster of vaccine breakthroughs. Vaccine breakthrough by a highly transmissible SARS-CoV-2 strain is a risk to global public health.

Methods: Nasopharyngeal swabs from suspected vaccine breakthrough cases were tested for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) by qPCR (quantitative polymerase chain reaction) for Wuhan-Hu1 and alpha variant. Positive samples were then sequenced by Swift Normalase Amplicon Panels to determine the causal variant. GATK (genome analysis toolkit) variants were filtered with allele fraction ≥80 and min read depth 30x.

Results: Viral sequencing revealed an infection cluster of 6 vaccinated patients infected with the delta (B.1.617.2) SARS-CoV-2 variant. With no history of vaccine breakthrough, this suggests the delta variant may possess immune evasion in patients that received the Pfizer BNT162b2, Moderna mRNA-1273, and Covaxin BBV152.

Conclusions: Delta variant may pose the highest risk out of any currently circulating SARS-CoV-2 variants, with previously described increased transmissibility over alpha variant and now, possible vaccine breakthrough.

Funding: Parts of this work was supported by the National Institute of Allergy and Infectious Diseases (1U19AI144297) and Baylor College of Medicine internal funding.

Keywords: B.1.617.2; COVID-19; Delta variant; Infectious disease; SARS-CoV-2.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • COVID-19 Vaccines
  • COVID-19*
  • Humans
  • Immune Evasion
  • SARS-CoV-2*

Substances

  • COVID-19 Vaccines
  • BNT162 vaccine